Electrophysiological effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor Dapagliflozin on human cardiac potassium channels
The sodium-glucose co-transporter-2 (SGLT2) inhibitor dapagliflozin is increasingly used in the treatment of diabetes and heart failure. Dapagliflozin has been associated with reduced incidence of atrial fibrillation (AF) in clinical trials. We hypothesized that the favorable antiarrhythmic outcome...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
23 May 2024
|
| In: |
International journal of molecular sciences
Year: 2024, Volume: 25, Issue: 11, Pages: 1-14 |
| ISSN: | 1422-0067 |
| DOI: | 10.3390/ijms25115701 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/ijms25115701 Verlag, kostenfrei, Volltext: https://www.mdpi.com/1422-0067/25/11/5701 |
| Author Notes: | Mara Elena Müller, Finn Petersenn, Juline Hackbarth, Julia Pfeiffer, Heike Gampp, Norbert Frey, Patrick Lugenbiel, Dierk Thomas and Ann-Kathrin Rahm |